# A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer

> **NCT00102219** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 77 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT00102219
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** 2007-10
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2007-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102219, "A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00102219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*